MORGAN STANLEY PLC/CALL/ROCHE GS/440/0.01/20.12.24 Stock

Warrant

DE000MB6A3Z2

Real-time Bid/Ask 11:43:35 2024-05-31 EDT
0.003 EUR / 0.04 EUR +633.33% Intraday chart for MORGAN STANLEY PLC/CALL/ROCHE GS/440/0.01/20.12.24
1 month-25.00%
3 months-57.14%
Date Price Change
24-05-31 0.003 0.00%
24-05-30 0.003 0.00%
24-05-29 0.003 0.00%
24-05-28 0.003 0.00%
24-05-27 0.003 0.00%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 09:56 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MB6A3Z
ISINDE000MB6A3Z2
Date issued 2023-05-16
Strike 440 CHF
Maturity 2024-12-20 (203 Days)
Parity 100 : 1
Emission price 0.07
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.028
Lowest since issue 0.002
Spread 0.038
Spread %95.00%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
228.3 CHF
Average target price
277.5 CHF
Spread / Average Target
+21.56%
Consensus